Gerald (Gerry) Friedland
Dr. Friedland's is Professor of Medicine and Epidemiology at the Yale School of Medicine. His major research interests are in the provision of HIV care to vulnerable populations and clinical trials of anti-retroviral agents, including adherence to HIV therapies and pharmacologic interaction studies between methadone and buprenorphine and antiretroviral agents. Dr Friedland is also involved in studies of HIV and risk reduction among HIV seropositives in clinical care and, most recently, in studies on the integration of care and treatment of tuberculosis and HIV disease in resource limited settings, notably South Africa. His group has uncovered the epidemic of XDR TB in South Africa and is working on epidemiologic, clinical and mycobacteriologic studies in this area.
More recently, he is working domestically on HIV/AIDS, a major focus my work has been to integrate HIV and TB care and treatment in co infected patients in South Africa with the aim of improving diagnosis, treatment and outcomes of both diseases. This has led to the recognition of the epidemic of extensively drug resistant tuberculosis (XDR TB) in Tugela Ferry in rural KwaZulu Natal South Africa and now focuses on the diagnosis, treatment and reduction of transmission of XDR TB and multiple drug resistant (MDR) TB and in HIV co-infected patients.